论文部分内容阅读
目的通过建立大鼠门脉高压背景下肝肿瘤模型,观察病理性脾脏的切除对肝肿瘤发生发展的影响。方法按照四氯化碳复合、梯段用药法制备大鼠肝硬化门脉高压模型,后将Walker-256肿瘤块种植在大鼠肝脏左外叶上,随机分组的A组大鼠在种植瘤块同时切除脾脏,B组大鼠保留脾脏。10d后分别测定两组大鼠的T细胞亚群CD4、CD8及CD4/CD8;切除大鼠肝脏左外叶,测量种植肿瘤块最大直径,并用免疫组织化学染色方法检测肿瘤组织Ki-67的表达。结果门脉高压模型建成后,大鼠的血常规以及肝功能指标出现明显异常。A组大鼠的CD4值和CD4/CD8比值均高于B组大鼠(0.36±0.01vs 0.35±0.02,1.33±0.08vs 1.24±0.05;P<0.05或P<0.01),而CD8值则低于B组大鼠(0.27±0.01vs0.29±0.02,P<0.01)。A组大鼠的肝脏肿瘤直径与B组大鼠比较差异无统计学意义。A组大鼠肿瘤组织的Ki-67阳性率较B组降低,差异具有统计学意义(P<0.05)。结论门脉高压状态下病理性脾脏的切除既有利于提高机体抗肿瘤的免疫力,又可以在一定程度上减弱肝肿瘤的侵袭能力。
Objective To establish a rat model of liver tumor in portal hypertension and observe the effect of pathological splenectomy on the development of hepatic tumor. Methods According to the carbon tetrachloride compound and ladder method, rat model of portal hypertension of liver cirrhosis was established. The Walker-256 tumor mass was implanted on the left outer lobe of rat liver. Rats in group A At the same time remove the spleen, B group rats retain spleen. After 10 days, the T cell subgroup CD4, CD8 and CD4 / CD8 of the two groups were respectively measured; the left outer lobe of the rat liver was excised and the maximum diameter of the tumor was measured. Ki-67 expression in the tumor tissue was detected by immunohistochemical staining . Results After establishment of portal hypertension model, blood routine and liver function indexes of rats were obviously abnormal. The CD4 and CD4 / CD8 ratios in group A were significantly higher than those in group B (0.36 ± 0.01 vs 0.35 ± 0.02, 1.33 ± 0.08 vs 1.24 ± 0.05; P <0.05 or P <0.01), while CD8 was lower The rats in group B (0.27 ± 0.01 vs 0.29 ± 0.02, P <0.01). There was no significant difference in the diameter of hepatic tumors between group A and group B. The Ki-67 positive rate of tumor in group A was lower than that in group B, the difference was statistically significant (P <0.05). Conclusions The resection of pathological spleen under portal hypertension is not only helpful to improve the anti-tumor immunity of the body, but also to a certain extent reduce the invasive ability of the liver tumor.